Pfizer Inc. (NYSE: PFE) beats adjusted Non-GAAP EPS consensus of approx. $0.68 per share in Q2 2026 earnings (4 August 2026, pre-market, confirmed by Pfizer press release)
Hit
✦ AI-generated prediction
Published on 23. July 2026
·
Predicted for 4. August 2026
·
Based on: Historical Cycle
Pfizer reports Q2 2026 results on August 4, 2026, pre-market. Analyst consensus is approximately $0.68 adjusted Non-GAAP EPS (TipRanks, as of July 2026). Pfizer confirmed FY2026 guidance at Q1 results (April 2026) and beat Q1 estimates. Growth drivers: oncology pipeline (Eliquis, Vyndaqel, Padcev), normalized RSV vaccine demand, and royalties. Headwinds: Paxlovid revenues continue normalizing, and generic competition in older products weighs on gross margin. Historical beat rate: approximately 70% over the last 12 quarters. No Polymarket market available.
Data basis for this prediction
- PFE Q2 2026 Earnings Date: 4. August 2026, vor Börseneröffnung (TipRanks, Stand 23.07.2026)
- PFE Analystenkon sens Q2 2026 EPS: ~0,68 USD Non-GAAP (TipRanks, Stand Juli 2026)
- PFE Q1 2026 bereinigtes EPS: 0,70 USD (beat 0,63 USD Konsens; Pfizer Pressemitteilung, 30.04.2026)
- Pfizer FY2026 EPS Guidance: 2,80–3,00 USD bereinigt (Pfizer Investor Relations, 30.04.2026)
Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.
Verdict: Hit
Pfizer meldete am 4. August 2026 vor Börseneröffnung ein bereinigtes Non-GAAP-EPS von 0,77 USD – damit wurde der Konsens von ca. 0,68 USD um 0,09 USD (≈ 13 %) übertroffen. Zusätzlich übertraf Pfizer auch beim Umsatz (15,03 Mrd. USD ggü. erwartetem Konsens von ca. 14,42 Mrd. USD) und hob den Mittelpunkt der Jahresumsatzguidance an (neu: 60,5–62,5 Mrd. USD). Quellen: Pfizer Q2-2026-Pressemitteilung (BusinessWire / Pfizer IR, 04.08.2026), CNBC, TechTimes, QZ.com.
📈 Economy
✦ AI
The S&P 500 closed at 7,636.36 on 9 September 2026. Falling below 7,450 by month-end would require a 2.4% decline. Headwinds: Fed rate hike of 25bp on 16 September (CentralBank.Watch: 59% probability), August PPI above expectations (+5.4% YoY), Iran-Gulf risk premium. Stabilizing factors: hike largely priced in (Polymarket: 93% for zero 2026 cuts), Q2 earnings solid, no recession signals. Historically, a single 25bp September hike rarely causes a monthly decline above 2.5%.
📈 Economy
✦ AI
Polymarket shows a 53% probability for a 25 basis point hike as of September 10, 2026. US Core CPI August 2026 (release September 11) is expected by market consensus to be above 3.0% YoY. The ECB raised its deposit rate by 25 bps to 2.50% on September 10, 2026 – an inflation-fighting signal that provides cover for the Fed. Against a hike: a mild slowdown in US industrial output. CME FedWatch also shows ~53% probability for a hike.
📈 Economy
✦ AI
The DAX closed at 25,562 points on September 9, 2026. A gain of +1.7% is required by month-end. Headwinds: ECB rate hike to 2.50% (September 10), 53% FOMC hike probability (September 16), persistently high oil prices (~$101/barrel Brent) weigh on energy-intensive DAX heavyweights. Tailwinds: strong SAP cloud growth expected, robust US demand, EUR/USD at 1.1644 benefits exporters. Implied 30-day volatility (VDAX): ~16%, corresponding to a σ range of roughly ±5.5% by month-end — the 26,000 level falls within the central distribution.